Isofundin

Magnesium chloride hexahydrate, potassium chloride, sodium chloride and calcium chloride dihydrate, the active ingredients in Isofundin, are an electrolyte solution presented as an injectable solution for intravenous use. It provides electrolyte replacement and fluid resuscitation in patients requiring restoration of extracellular fluid volume and maintenance of electrolyte balance. It is indicated for use in surgical, trauma, and intensive care settings where rapid correction of electrolyte deficits is essential.

GNH USA supplies Isofundin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Isofundin is an intravenous electrolyte solution used to correct disturbances in fluid and electrolyte balance. - Electrolyte replacement: Restores magnesium, potassium, sodium and calcium levels in patients with documented deficits. - Fluid resuscitation: Provides isotonic fluid volume to support circulatory volume in hypovolemic states such as hemorrhage or severe dehydration. - Maintenance of electrolyte balance: Helps sustain normal electrolyte concentrations during prolonged fasting, surgery, or critical illness. - Post‑operative care: Supports electrolyte homeostasis after major surgery. - Burn injuries: Supplies necessary ions to counteract losses from extensive fluid shifts.

Isofundin may be associated with infusion‑related adverse reactions.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the catheter site. - Transient hypermagnesemia: temporary elevation of serum magnesium. - Nausea or vomiting: mild gastrointestinal upset. - Headache: mild to moderate headache during or after infusion.

Serious or Rare Side Effects: - Severe hypermagnesemia: can cause hypotension, respiratory depression, or cardiac arrhythmia. - Severe hyperkalemia: may lead to life‑threatening cardiac arrhythmias. - Anaphylactic reaction: rare systemic allergic response.

When using Isofundin, clinicians should observe specific precautions to ensure patient safety. - Assess electrolyte levels: obtain baseline serum magnesium, potassium, sodium and calcium before infusion. - Adjust dose in renal impairment: reduce infusion rate or volume in patients with reduced renal clearance. - Monitor cardiac rhythm: continuous ECG monitoring is advised during rapid correction of potassium or magnesium. - Avoid in hyperkalemia: do not administer if serum potassium is already elevated beyond therapeutic range. - Use aseptic technique: ensure sterile handling to prevent contamination of the injectable solution. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Isofundin can interact with other medications that affect electrolyte balance or cardiac conduction.

Major Interactions (Avoid): - Calcium channel blockers: may potentiate hypercalcemia when combined with high calcium infusion. - Digoxin: increased risk of arrhythmia with concurrent hyperkalemia. - Loop diuretics: may cause rapid shifts in potassium and magnesium levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor potassium levels to avoid hyperkalemia. - Beta‑adrenergic agonists: may influence serum potassium distribution. - Antacids containing magnesium or aluminum: assess cumulative magnesium load.